The University of Chicago Header Logo

Connection

Lucy Godley to Middle Aged

This is a "connection" page, showing publications Lucy Godley has written about Middle Aged.
Connection Strength

0.465
  1. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103.
    View in: PubMed
    Score: 0.038
  2. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016 10 06; 128(14):1800-1813.
    View in: PubMed
    Score: 0.038
  3. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
    View in: PubMed
    Score: 0.025
  4. Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. Am J Hematol. 2021 09 01; 96(9):E327-E330.
    View in: PubMed
    Score: 0.013
  5. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021 11; 35(11):3245-3256.
    View in: PubMed
    Score: 0.013
  6. Inherited Thrombocytopenia Caused by Germline ANKRD26 Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome. J Investig Med High Impact Case Rep. 2020 Jan-Dec; 8:2324709620938941.
    View in: PubMed
    Score: 0.012
  7. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638.
    View in: PubMed
    Score: 0.011
  8. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018 01 23; 2(2):146-150.
    View in: PubMed
    Score: 0.011
  9. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.
    View in: PubMed
    Score: 0.011
  10. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.011
  11. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
    View in: PubMed
    Score: 0.010
  12. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia. 2017 05; 31(5):1226-1229.
    View in: PubMed
    Score: 0.010
  13. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2.
    View in: PubMed
    Score: 0.009
  14. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr; 17(4):496-508.
    View in: PubMed
    Score: 0.009
  15. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.
    View in: PubMed
    Score: 0.009
  16. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.009
  17. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood. 2016 Feb 25; 127(8):1017-23.
    View in: PubMed
    Score: 0.009
  18. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13.
    View in: PubMed
    Score: 0.009
  19. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.009
  20. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015 Nov 26; 126(22):2484-90.
    View in: PubMed
    Score: 0.009
  21. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015 May 11; 27(5):658-70.
    View in: PubMed
    Score: 0.009
  22. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
    View in: PubMed
    Score: 0.009
  23. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014 Oct 10; 32(29):3264-74.
    View in: PubMed
    Score: 0.008
  24. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9.
    View in: PubMed
    Score: 0.008
  25. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013 Sep; 3(9):1002-19.
    View in: PubMed
    Score: 0.008
  26. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43.
    View in: PubMed
    Score: 0.008
  27. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.
    View in: PubMed
    Score: 0.008
  28. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9.
    View in: PubMed
    Score: 0.008
  29. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15.
    View in: PubMed
    Score: 0.007
  30. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.007
  31. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 2012 Feb; 7(2):201-7.
    View in: PubMed
    Score: 0.007
  32. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
    View in: PubMed
    Score: 0.007
  33. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45.
    View in: PubMed
    Score: 0.007
  34. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res. 2011 Apr 15; 17(8):2170-80.
    View in: PubMed
    Score: 0.007
  35. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301.
    View in: PubMed
    Score: 0.007
  36. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.
    View in: PubMed
    Score: 0.006
  37. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
    View in: PubMed
    Score: 0.006
  38. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
    View in: PubMed
    Score: 0.006
  39. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8.
    View in: PubMed
    Score: 0.006
  40. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.006
  41. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
    View in: PubMed
    Score: 0.006
  42. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
    View in: PubMed
    Score: 0.005
  43. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008 Apr 15; 14(8):2444-9.
    View in: PubMed
    Score: 0.005
  44. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.005
  45. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
    View in: PubMed
    Score: 0.005
  46. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805.
    View in: PubMed
    Score: 0.005
  47. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.
    View in: PubMed
    Score: 0.005
  48. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10.
    View in: PubMed
    Score: 0.005
  49. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.